Propel Bio Management
Latest statistics and disclosures from Propel Bio Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLT, HIGH, TCRX, MDGL, ACHV, and represent 63.14% of Propel Bio Management's stock portfolio.
- Added to shares of these 9 stocks: HIGH (+$25M), ACHV (+$11M), AKRO (+$5.8M), APLT (+$5.0M), PHAT, MDGL, SNDX, TRVI, Eiger Biopharmaceuticals.
- Started 4 new stock positions in TRVI, SNDX, Eiger Biopharmaceuticals, ACHV.
- Reduced shares in these 10 stocks: PAGP (-$22M), CRNX (-$5.9M), Fidelity Inv Mmtrsy 1 680, BSV, IBDP, , Eiger Biopharmaceuticals, SLQD, , HRTX.
- Sold out of its positions in AGIO, CRNX, Eiger Biopharmaceuticals, HRTX, SLQD, IBDP, PAGP, SPSB, FLRN, BSV.
- Propel Bio Management was a net buyer of stock by $19M.
- Propel Bio Management has $171M in assets under management (AUM), dropping by 41.83%.
- Central Index Key (CIK): 0001969764
Tip: Access up to 7 years of quarterly data
Positions held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 28 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Applied Therapeutics Comm (APLT) | 24.3 | $42M | +13% | 6.1M | 6.80 |
|
| Plains Gp Holdings Lp-cl Comm (HIGH) | 15.9 | $27M | +1141% | 1.5M | 18.25 |
|
| Tscan Therapeutics Comm (TCRX) | 9.7 | $17M | 2.1M | 7.94 |
|
|
| Madrigal Pharmaceuticals Comm (MDGL) | 6.7 | $12M | +43% | 43k | 267.04 |
|
| Achieve Life Sciences Comm (ACHV) | 6.5 | $11M | NEW | 2.5M | 4.54 |
|
| Phathom Pharmaceuticals Comm (PHAT) | 5.4 | $9.2M | +96% | 870k | 10.62 |
|
| Akero Therapeutics Comm (AKRO) | 4.8 | $8.3M | +227% | 328k | 25.26 |
|
| Fulcrum Therapeutics Comm (FULC) | 4.1 | $7.1M | 750k | 9.44 |
|
|
| Avidity Biosciences Comm (RNA) | 2.7 | $4.6M | 179k | 25.52 |
|
|
| Day One Biopharmaceuticals I Comm (DAWN) | 2.6 | $4.5M | 271k | 16.52 |
|
|
| Ardelyx Comm (ARDX) | 2.5 | $4.3M | 594k | 7.30 |
|
|
| Athira Pharma Comm (ATHA) | 2.4 | $4.1M | 1.5M | 2.74 |
|
|
| Kura Oncology Comm (KURA) | 1.6 | $2.8M | 130k | 21.33 |
|
|
| Telesat Corp Comm (TSAT) | 1.5 | $2.5M | 291k | 8.60 |
|
|
| Kymera Therapeutics Comm (KYMR) | 1.3 | $2.3M | 56k | 40.20 |
|
|
| Ishares Mbs Etf Comm (MBB) | 1.2 | $2.1M | 22k | 92.42 |
|
|
| Syndax Pharmaceuticals Comm (SNDX) | 1.2 | $2.0M | NEW | 83k | 23.80 |
|
| Mirum Pharmaceuticals Comm (MIRM) | 1.0 | $1.8M | 70k | 25.12 |
|
|
| Marinus Pharmaceuticals Comm (MRNS) | 1.0 | $1.6M | 180k | 9.04 |
|
|
| Kayne Anderson Energy Inf Comm (KYN) | 0.9 | $1.5M | 147k | 10.01 |
|
|
| Sutro Biopharma Comm (STRO) | 0.6 | $1.1M | 195k | 5.65 |
|
|
| Trevi Therapeutics Comm (TRVI) | 0.5 | $897k | NEW | 260k | 3.45 |
|
| X4 Pharmaceuticals Comm (XFOR) | 0.4 | $744k | 535k | 1.39 |
|
|
| Eiger Biopharmaceuticals Comm | 0.4 | $732k | NEW | 146k | 5.00 |
|
| Ishares Iboxx Investment Comm (LQD) | 0.3 | $485k | 4.5k | 108.92 |
|
|
| Cybin Comm (CYBN) | 0.2 | $352k | 850k | 0.41 |
|
|
| Fidelity Inv Mmtrsy 1 680 Comm | 0.1 | $212k | -95% | 212k | 1.00 |
|
| Chinook Therapeutics Inc Cvr Comm | 0.0 | $31k | 79k | 0.39 |
|
Past Filings by Propel Bio Management
SEC 13F filings are viewable for Propel Bio Management going back to 2023
- Propel Bio Management 2024 Q1 filed May 13, 2024
- Propel Bio Management 2023 Q4 filed Feb. 14, 2024